Overview
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2021-11-01
2021-11-01
Target enrollment:
Participant gender: